| Literature DB >> 31753799 |
Natalia Milosevich1, James McFarlane1, Michael C Gignac1, Janessa Li1, Tyler M Brown1, Chelsea R Wilson1, Lindsey Devorkin2, Caitlin S Croft1, Rebecca Hof1, Irina Paci1, Julian J Lum2, Fraser Hof3.
Abstract
Epigenetic regulation of gene expression is in part controlled by post-translational modifications on histone proteins. Histone methylation is a key epigenetic mark that controls gene transcription and repression. There are five human polycomb paralog proteins (Cbx2/4/6/7/8) that use their chromodomains to recognize trimethylated lysine 27 on histone 3 (H3K27me3). Recognition of the methyllysine side chain is achieved through multiple cation-pi interactions within an 'aromatic cage' motif. Despite high structural similarity within the chromodomains of this protein family, they each have unique functional roles and are linked to different cancers. Selective inhibition of different CBX proteins is desirable for both fundamental studies and potential therapeutic applications. We report here on a series of peptidic inhibitors that target certain polycomb paralogs. We have identified peptidic scaffolds with sub-micromolar potency, and will report examples that are pan-specific and that are partially selective for individual members within the family. These results highlight important structure-activity relationships that allow for differential binding to be achieved through interactions outside of the methyllysine-binding aromatic cage motif.Entities:
Keywords: CBX; Epigenetics; Methyllysine reader proteins; Peptidomimetics; Polycomb paralogs
Mesh:
Substances:
Year: 2019 PMID: 31753799 DOI: 10.1016/j.bmc.2019.115176
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641